Gossamer Bio, Inc. (GOSS) Stock Score, Valuation & Financial Research

Gossamer Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GOSS

Gossamer Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.85. These figures are a research snapshot, not a buy or sell recommendation.

What Gossamer Bio, Inc. does

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Gossamer Bio is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on research and development of product candidates, specifically seralutinib, and it expects to fund operations through equity or debt financing and potential future commercialization or licensing agreements.

Products and services

  • The company is focused on the development of seralutinib, an inhaled small molecule PDGFR inhibitor, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Customer types

Healthcare providers and patients (potential future).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — Third-party organizations engaged to conduct pre-clinical and clinical trials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Chiesi Group — A global collaboration agreement for the joint development of seralutinib. Source

Business strengths to evaluate

  • Clinical development of seralutinib in Phase 3 Source

Business risks and research considerations

  • Limited operating history and history of losses Source
  • Dependence on the success of a single product candidate, seralutinib Source
  • Requirement for substantial additional financing Source

Sources: Company research source · Chiesi Group

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GOSS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.85
Market capitalization:
72.41M (currency not supplied)
Revenue:
USD 53.29M
Net income:
USD -125.22M
Free cash flow:
USD -171.35M
Cash:
USD 41.15M
Total debt:
USD 39.1M
EPS:
USD -45.32

What stands out

  • Reported year-over-year revenue growth is +9.9%.
  • Free cash flow is USD -171.35M, negative for the stored period.
  • The balance sheet shows USD 41.15M of cash versus USD 39.1M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -321.6% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -235.0% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 2.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GOSS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can GOSS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can GOSS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does GOSS's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for GOSS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GOSS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research GOSS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.